NASDAQ:IMVT Immunovant Q4 2025 Earnings Report $15.27 -0.26 (-1.68%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Immunovant EPS ResultsActual EPS-$0.64Consensus EPS -$0.72Beat/MissBeat by +$0.08One Year Ago EPS-$0.52Immunovant Revenue ResultsActual Revenue$0.16 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmunovant Announcement DetailsQuarterQ4 2025Date5/29/2025TimeBefore Market OpensConference Call DateThursday, May 29, 2025Conference Call Time7:00AM ETUpcoming EarningsImmunovant's Q2 2026 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Immunovant Earnings HeadlinesImmunovant (IMVT) Highlights New Graves’ Disease Data Can Its Pipeline Deliver Sustainable Innovation?September 11, 2025 | finance.yahoo.comA Look at Immunovant's Valuation Following New Batoclimab Data Update for Graves' DiseaseSeptember 9, 2025 | finance.yahoo.comWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.September 16 at 2:00 AM | SmartAsset (Ad)Immunovant: 80% of patients demonstrate response in Graves’ disease trialSeptember 4, 2025 | msn.comRoivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data TranscriptSeptember 3, 2025 | seekingalpha.comImmunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease PatientsSeptember 3, 2025 | globenewswire.comSee More Immunovant Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email. Email Address About ImmunovantImmunovant (NASDAQ:IMVT) Inc. is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia. The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG. Efgartigimod is being evaluated in late-stage clinical trials for generalized myasthenia gravis and other indications, and has demonstrated the potential to provide rapid and durable reductions in pathogenic IgG levels. In addition to efgartigimod, Immunovant is advancing a pipeline of next-generation FcRn-targeted monoclonal antibodies designed to address a range of antibody-mediated diseases. Founded in 2017 as a spin-out of Roivant Sciences, Immunovant is headquartered in New York, with research and development activities spanning North America and Europe. The company’s clinical programs involve global trial sites across key regions, and its leadership team comprises experienced executives and scientists with deep expertise in immunology and biologics development. Immunovant continues to collaborate with academic institutions and strategic partners to advance its FcRn-focused platform toward regulatory approval and commercial readiness.View Immunovant ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
